The FDA has accepted GSK’s application for priority review for extended use of Arexvy in higher-risk adults aged 50 to 59 years; pharmacy retail chains are finding it harder to draw the next generation of pharmacists; antivaccine activists are falsely downplaying the dangers of measles amid global outbreaks.